Literature DB >> 30888921

Biomarkers of Autoimmunity in Acute Psychiatric Disorders.

Sverre Georg Sæther1, Anne Dorthea Bjerkenes Rø1, Jeanette Brun Larsen1, Arne Vaaler1, Daniel Kondziella1, Solveig Klæbo Reitan1.   

Abstract

OBJECTIVE: Previous studies have suggested that autoantibodies associated with systemic autoimmune disorders are more prevalent in patients with psychotic and affective disorders compared with healthy control subjects. However, most positive studies addressing this issue have been limited by small sample sizes and lack of correction for confounding factors. The authors aimed to assess the prevalence of several autoantibodies in patients admitted to acute psychiatric inpatient care and investigate whether patients with psychotic and affective disorders have an increased prevalence of autoantibodies compared with psychiatric patients admitted for other reasons.
METHODS: Five hundred eighty-five patients were screened for the presence of antinuclear antibodies (ANA), anticardiolipin and antibeta2-glycoprotein, antithyroid peroxidase (anti-TPO), antitissue transglutaminase IgA, antigliadin deamidated peptide IgG, and rheumatoid factor IgM (RF). Differences in prevalence between patients with nonaffective psychoses (N=105), bipolar disorders (N=78), unipolar depressive disorders (N=146), and other reasons for admission (N=256) were assessed using chi-square tests and logistic regression models.
RESULTS: One or more autoantibodies were present in 26.2% of the patients, including ANA (9.4%), RF (9.2%), and anti-TPO (5.6%). Autoantibody prevalence increased with age (odds ratio=1.21, 95% CI=1.09-1.35) and smoking status (odds ratio=1.99, 95% CI=1.04-3.82) but was not associated with a diagnosis of a psychotic or affective disorder.
CONCLUSIONS: Autoimmune autoantibodies seem to be equally prevalent in patients with acute psychiatric conditions with and without psychotic and affective disorders. This result challenges the idea that these autoantibodies have specificity for certain psychiatric disorders.

Entities:  

Keywords:  Antibody Organic Mental Disorders Schizophrenia Neuroimmunology

Mesh:

Substances:

Year:  2019        PMID: 30888921     DOI: 10.1176/appi.neuropsych.18040069

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  3 in total

1.  Catalytic Antibodies in Bipolar Disorder: Serum IgGs Hydrolyze Myelin Basic Protein.

Authors:  Daria A Kamaeva; Liudmila P Smirnova; Svetlana N Vasilieva; Daria V Kazantseva; Alisa R Vasilieva; Svetlana A Ivanova
Journal:  Int J Mol Sci       Date:  2022-07-02       Impact factor: 6.208

2.  Redefining the Cut-Off Ranges for TSH Based on the Clinical Picture, Results of Neuroimaging and Laboratory Tests in Unsupervised Cluster Analysis as Individualized Diagnosis of Early Schizophrenia.

Authors:  Natalia Śmierciak; Marta Szwajca; Tadeusz J Popiela; Amira Bryll; Paulina Karcz; Paulina Donicz; Aleksander Turek; Wirginia Krzyściak; Maciej Pilecki
Journal:  J Pers Med       Date:  2022-02-09

3.  Diagnosing Organic Causes of Schizophrenia Spectrum Disorders: Findings from a One-Year Cohort of the Freiburg Diagnostic Protocol in Psychosis (FDPP).

Authors:  Dominique Endres; Miriam Matysik; Bernd Feige; Nils Venhoff; Tina Schweizer; Maike Michel; Sophie Meixensberger; Kimon Runge; Simon J Maier; Kathrin Nickel; Karl Bechter; Horst Urbach; Katharina Domschke; Ludger Tebartz van Elst
Journal:  Diagnostics (Basel)       Date:  2020-09-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.